Use of Risperidone in ECT for Treatment Resistant Depression

Stopped early · Phase 4

Conditions studied: Major Depression

In brief

The purpose of this study is to determine if the combination of risperidone and ECT improves a patient's response in depression compared to ECT alone.

Key facts

Study ID

NCT00203723

Run by

University of California, Los Angeles

People needed

45

Starts

2005-03-01

Expected to finish

2006-05-01

Last updated by the study team

2006-05-18

Who can join

Age: 18 and older, up to 89. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age between 18 to 89 years, inclusive
• Male or female
• Inpatient or outpatient ECT with a current diagnosis of unipolar or bipolar depression, with or without psychosis, according to DSM-IV criteria. HAM-D (17-item) score > 17 and MADRS score > 18 at screening and at first treatment session.

You may not qualify if…

• MMSE < 23
• Inability to consent to ECT
• Current diagnosis of schizophrenia or schizoaffective disorder
• Current diagnosis of Parkinson's Disease or any Dementia, including Lewy Body Disease
• History of allergic reaction to risperidone
• History of Neuroleptic Malignant Syndrome
• Current pregnancy or positive urine pregnancy test
• Women who are breast-feeding
• Active alcohol or illicit substance abuse

Where it is running

• UCLA Npi&H — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.